Nanopore Based Methods for Enantiomer Differentiation

描述(由申请人提供)：这一第一阶段计划的总体目标是开发一个新的、强大的纳米孔平台，用于在临床样本中区分药理上相关的对映体。对映体筛选是药物生产和药代动力学研究的一个重要方面。为了确定给药后机体对药物的作用，需要检测下限低的快速分析方法。EBS计划在我们目前的玻璃纳米孔技术的基础上扩展，以开发一个能够进行这种级别检测的强大平台。该项目将极大地改进目前的对映体鉴别方法，减少操作时间和成本，并使更多的研究人员、医疗专业人员和药物制造商能够获得先进的对映体筛选能力。 与公共卫生相关：一种新的高度稳定的纳米孔平台正在开发中，该平台非常适合感官对映体筛选应用。该平台的健壮性将允许以低成本分析临床样本，所需的时间和仪器最少。

DESCRIPTION (provided by applicant): The overall aim of this Phase I program is to develop a new, robust nanopore platform for the differentiation of pharmacologically relevant enantiomers in clinical samples. Enantiomer screening is an important aspect of drug manufacturing and pharmacokinetic studies. In order to determine what an organism's body does to a drug after administration, rapid analysis methods with low limits of detection are needed. EBS plans to expand on our current glass nanopore technology to develop a robust platform capable of this level of detection. This project will greatly improve on current enantiomer differentiation methods, reducing operating times and costs, and making advanced enantiomer screening capabilities available to more researchers, medical professionals, and drug manufacturers. PUBLIC HEALTH RELEVANCE: A new highly-stable nanopore platform that is ideally suited for sensory enantiomer screening applications is being developed. The robustness of this platform will allow clinical samples to be analyzed at a low cost, with minimal time and instrumentation needed.